From Pulse 2.0 · Amit Chowdhry · · 1m 10s
Epicrispr Biotechnologies Gets $8M CIRM Grant for FSHD Therapy
Epicrispr Biotechnologies receives $8 million CIRM grant to advance EPI-321 for FSHD treatment.
In brief
Epicrispr Biotechnologies receives $8 million CIRM grant to advance EPI-321 for FSHD treatment. Epicrispr Biotechnologies gets $8 million from CIRM to develop EPI-321, an epigenetic therapy for facioscapulohumeral muscular dystrophy. Originally reported by Pulse 2.0.
Epicrispr Gets $8M CIRM Grant
Epicrispr Biotechnologies has been awarded an $8 million grant from the California Institute for Regenerative Medicine to support the ongoing first-in-human Phase 1/2 clinical trial of EPI-321, its investigational epigenetic therapy for facioscapulohumeral muscular dystrophy.
EPI-321 Targets DUX4 Expression
The therapy is designed to durably silence expression of DUX4, the genetic driver of FSHD, without altering the underlying DNA sequence.
FSHD Has No Approved Treatments
FSHD is a progressive genetic neuromuscular disease with no approved disease-modifying treatments for patients.
Clinical Data Shows Encouraging Results
Epicrispr reported increases in lean muscle volume and strength following a single administration of EPI-321 in the ongoing study.
CIRM Award Follows Clinical Presentation
The CIRM award follows Epicrispr’s presentation of six-month clinical data at the 31st Annual Congress of the World Muscle Society.
Here's the gist
Epicrispr Biotechnologies gets $8 million from CIRM to develop EPI-321, an epigenetic therapy for facioscapulohumeral muscular dystrophy.
